CHLOROTOXIN
GBM
TransMolecularprotein_peptidePhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the GBM cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lapatinib National Cancer Institute (NCI) | Phase 2 | BB |
LENVATINIB Tel Aviv Medical Center | Phase 2 | BB |
FET Thomas Hope | Phase 2 | B |
MANNITOL Northwell Health | Phase 2 | B |
Silevertinib Black Diamond Therapeutics, Inc. | Phase 2 | B |
View all 18 →
Same molecule, other indications
CHLOROTOXIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →